An Innovative Canadian Pharmaceutical Company

Revenue Projected at $160,000,000 by 2025

Sponsored
Message: INTERVIEW ALERT: Valeo Pharma (VPH: CSE) (VPHIF: OTCQB)

We just sat down with CEO Steve Saviuk.

We discuss:

  • Listing of blood thinner drug with 2 group purchasing organizations
  • Agreement Supports $30M Annual Revenue Target From Blood Thinner Product Alone
  • Represents 700 hospital and healthcare facilities across Canada

OUT TONIGHT

 

Share
New Message
Please login to post a reply